Diabetes Surge Drives Novo Nordisk To Expand Organically In Emerging Markets As Sanofi Moves To Buy
This article was originally published in PharmAsia News
Executive Summary
An expected surge in the number of diabetic patients has prompted the world’s biggest insulin manufacturer to build up resources in emerging markets, most recently unveiling its largest overseas R&D center, while rival Sanofi eyes acquisitions.